Table 2.
Efficacy measures by FMMA scores for each intervention group (N = 6 for BCI-HK, n = 8 for HK, and N = 7 for SAT).
| Outcome | Group | Baseline | Improvements relative to week 0 | |||
|---|---|---|---|---|---|---|
| Week 0 | Week 3 | Week 6 | Week 12 | Week 24 | ||
| Proximal (0~42) | BCI-HK | 24.2 ± 7.5 | 3.3 ± 4.2 | 3.8 ± 2.7 | 5.0 ± 2.4 | 5.5 ± 2.1 |
| HK | 19.5 ± 7.7 | 2.3 ± 2.7 | 4.4 ± 2.7 | 4.0 ± 3.5 | 5.8 ± 2.9 | |
| SAT | 18.1 ± 10.4 | 1.1 ± 2.2 | 3.0 ± 2.7 | 2.6 ± 4.4 | 3.3 ± 4.0 | |
| Distal (0~24) | BCI-HK | 8.8 ± 9.2 | 2.5 ± 2.4 | 3.3 ± 2.3 | 3.2 ± 2.7 | 4.2 ± 3.1 |
| HK | 6.0 ± 4.7 | 1.6 ± 2.5 | 2.9 ± 3.0 | 2.5 ± 2.6 | 2.5 ± 3.0 | |
| SAT | 5.3 ± 4.7 | 0.4 ± 1.1 | 1.9 ± 1.9 | 1.0 ± 1.3 | 0.3 ± 2.1 | |
| Upper Extremity (0~66) | BCI-HK | 33.0 ± 16.2 | 5.8 ± 4.7 | 7.2 ± 2.3 | 8.2 ± 2.9 | 9.7 ± 2.9 |
| HK | 25.5 ± 11.5 | 3.9 ± 4.3 | 7.3 ± 4.7 | 6.5 ± 4.4 | 8.3 ± 5.0 | |
| SAT | 23.4 ± 14.5 | 1.6 ± 2.2 | 4.9 ± 4.1 | 3.6 ± 5.5 | 3.6 ± 5.9 | |